The Food and Drug Administration (FDA) approved a drug on Friday to regain the sexual desire for premenopausal women suffering from a disorder of hypoactive sexual desire. at least 45 minutes before the expected sexual activity and activates brain pathways involved in sexual desire. This is the last attempt to find what some have said would be equivalent to the male viagra. pharmacological treatment. Today's approval gives women the option of another treatment for this condition, "said Hylton V. Joffe, director of the Center for Drug Assessment and Bone Studies, Reproductive and Urological Products, in a press release. The FDA's commitment to protecting and improving women's health, we will continue to support the development of safe and effective treatments for female sexual dysfunction. Addyi, her main competitor. It also includes tolerable side effects, the most common being nausea.
AMAG Pharmaceuticals is a drug developer. a website that offers women information on this condition.